Aspirin -acetylsalicylic acid / Risk Cancer Research Results

ASA, Aspirin -acetylsalicylic acid: Click to Expand ⟱
Features: nonsteroidal anti-inflammatory drug (NSAID)
Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory.

-Aspirin irreversibly inhibits the enzyme cyclooxygenase-1 (COX-1). This inhibition reduces the production of thromboxane A₂, a potent promoter of platelet aggregation.
-low-dose aspirin is frequently used for the prevention of cardiovascular events such as heart attacks and strokes in individuals at risk.

Aspirin (acetylsalicylic acid; ASA) — an acetylating salicylate NSAID that irreversibly inhibits cyclooxygenase (COX) enzymes, producing anti-inflammatory, analgesic/antipyretic, and (at low dose) antiplatelet effects via sustained suppression of platelet thromboxane A₂ (TXA₂). It is a small-molecule oral drug (OTC and prescription formulations; immediate-release and enteric-coated). Standard abbreviations include ASA and “low-dose aspirin” (typically 75–100 mg/day in many guidelines/trials). In cancer biology, the most industry-relevant hypotheses center on platelet COX-1/TXA₂ suppression (metastasis/immune effects) plus COX-2/PGE₂ suppression (inflammatory tumor microenvironment), with clinical signals that are context- and biomarker-dependent.

Primary mechanisms (ranked):

  1. Platelet COX-1 acetylation → TXA₂ ↓ → platelet activation/aggregation ↓ (systemic antiplatelet axis; downstream effects on thrombosis and platelet–tumor biology)
  2. COX-2 activity modulation/inhibition → prostanoid signaling (including PGE₂) ↓ (anti-inflammatory and tumor-microenvironment effects; more dose/context dependent than platelet COX-1)
  3. Platelet-derived TXA₂ immunosuppression axis ↓ (T-cell suppression relieved; metastasis permissiveness reduced) (context-dependent; mechanistically linked to platelet COX-1/TXA₂)
  4. Immune checkpoint/inflammation coupling: PD-L1 ↓ and inflammatory mediators ↓ (model- and tissue-dependent; partly COX/prostanoid-linked and partly epigenetic/transcriptional)
  5. Pro-apoptotic balance shift in some models (BAX ↑, Bcl-2 ↓, apoptosis ↑) (secondary; model-dependent)

Bioavailability / PK relevance: Oral absorption is generally rapid (formulation-dependent). Aspirin itself is short-lived in plasma due to rapid deacetylation to salicylate, while platelet COX-1 inhibition persists for the platelet lifespan (functional persistence despite short plasma exposure). Salicylate elimination can become dose-dependent (capacity-limited) at higher doses, extending effective half-life and increasing toxicity/bleeding risk.

In-vitro vs systemic exposure relevance: Many anti-proliferative or direct tumor-cell cytotoxic effects reported in vitro occur at concentrations not typically achieved with low-dose antiplatelet regimens; clinically plausible cancer effects at low dose are more consistent with platelet/immune/microenvironment mechanisms than direct tumor cytotoxicity.

Clinical evidence status: Strong clinical use exists for antiplatelet indications (cardiovascular secondary prevention and other clinician-directed uses). For primary prevention, contemporary guidance restricts initiation due to bleeding risk (age/risk stratified). For oncology, evidence supports chemopreventive associations (strongest for colorectal cancer in long-term use) and emerging biomarker-stratified adjuvant signals (e.g., PI3K-pathway–altered CRC recurrence reduction in a large randomized setting), but this is not universal across populations and may be age- and context-dependent.

**There is debate about the reduced cancer risk effects of aspirin when used long term (10yr). The evidence is stronger for CRC especially for those with IBD. Evidence is more debatable for those 70yrs old. Also there are claims about the anti-Metastasis capabilites of aspirin for those with cancer.

Mechanistic and translation-relevant axes for aspirin (ASA) in cancer

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Platelet COX-1 → TXA₂ Indirect: platelet shielding of CTCs ↓; platelet-assisted extravasation/metastatic seeding ↓ (context-dependent) Platelet aggregation ↓; hemostasis capacity ↓ (bleeding risk ↑) P Antiplatelet state via irreversible COX-1 acetylation High mechanistic centrality at low dose because platelets cannot resynthesize COX-1; effects persist beyond plasma aspirin exposure.
2 COX-2 → PGE₂ inflammatory tumor microenvironment Inflammatory prostanoid signaling ↓; pro-tumor inflammation ↓ (dose/context dependent) GI mucosal protection ↓ (ulcer/bleeding risk ↑); renal prostaglandin effects (risk in susceptible patients) R Anti-inflammatory prostanoid suppression COX-2 modulation is less selectively targeted than platelet COX-1 at “low-dose”; relevance increases with higher systemic exposure.
3 Platelet TXA₂ → T-cell suppression axis Anti-metastatic immunity ↑ (T-cell effector function ↑; metastasis permissiveness ↓) Immune modulation ↔ (context-dependent) R Release of T-cell suppression linked to platelet TXA₂ Mechanistic bridge between antiplatelet action and metastasis control; aligns with platelet-first hypothesis for low-dose aspirin.
4 PI3K-pathway–altered CRC recurrence signal Recurrence risk ↓ in PI3K-altered localized CRC (biomarker-stratified benefit) Systemic bleeding risk ↑ remains G Genotype-linked clinical leverage (adjuvant context) Represents actionable stratification logic: benefit concentrated in molecular subsets rather than pan-CRC.
5 Immune checkpoint coupling: PD-L1 PD-L1 ↓ (model-dependent) → immune evasion ↓ (context-dependent) Immune effects ↔ G Potential immunomodulatory adjunct axis Reported in specific tumor models via transcription/epigenetic regulators; translation likely tumor-type and context dependent.
6 Apoptosis balance Apoptosis ↑; BAX ↑; Bcl-2 ↓ (model-dependent) Cell stress/irritation ↔ (context-dependent) G Secondary pro-death signaling in some models Often requires higher concentrations than antiplatelet dosing; treat as supportive rather than primary for real-world low-dose exposure.
7 Clinical Translation Constraint Benefit heterogeneity ↑ (tumor subtype, age, bleeding risk, concomitant therapy) GI bleeding ↑; hemorrhagic stroke risk ↑ (baseline-dependent); hypersensitivity in susceptible patients G Therapeutic window constrained by bleeding and population selection Major limiter for preventive use in older adults; drug–drug interactions (anticoagulants/other NSAIDs) and peri-procedural management are practical constraints.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Risk, Risk: Click to Expand ⟱
Source:
Type:
Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive. 
Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral




CRIS Exposure / Compound Evidence Cancers Notes




-5 Exercise (overall)
VStrong Hum BC, CRC, Endo, PCa, Liv






-5 Aerobic + resistance VStrong Hum Broad inc + mort






-4 Aerobic exercise (mod–vig) VStrong Hum BC, CRC, Endo






-4 Resistance training (alone) Strong Hum BC, CRC






-3 High-intensity interval training Mod–Strong Hum BC, CRC






-2 NEAT / low-intensity activity Moderate Hum CRC






-5 Cruciferous vegetable pattern Strong Hum Lung, CRC, BC, PCa






-5 Sunlight exposure (physiologic) Strong Hum CRC, BC, PCa






-4 Fasting (metabolic pattern)
Strong Mech + Hum BC, CRC, PCa 






-4 Curcumin
Hum + Pre GI, BC, PCa






-4 Sulforaphane
Hum + Pre Lung, CRC, BC






-4 PEITC
Hum + Pre Lung, CRC, PCa






-4 EGCG (tea matrix)
Strong Hum GI, PCa, BC






-4 Lycopene
Strong Hum PCa






-4 Apigenin
Pre + Diet Hum BC, PCa, CRC 






-4 Luteolin
Pre + Diet Hum Lung, CRC, BC 






-4 Kaempferol
Diet Hum Ov, Panc, Lung






-4 Fisetin
Pre + Early Hum CRC, PCa, Mel






-4 Ellagic acid → Urolithin A
Hum (microbiome) CRC, PCa, BC






-3 Omega-3 (EPA/DHA)
Strong Hum CRC, BC






-3 Vitamin D3 (supp)
Obs + RCT CRC, BC






-3 Garlic (allicin)
Mod Hum GI






-3 Mushroom beta-glucans
Hum adjunct GI, BC






-3 Melatonin
Hum + Mech BC, PCa






-3 Coffee (whole)
Strong Hum Liv, Endo






-2 Quercetin
Limited Hum Lung, CRC






-2 Resveratrol
Limited Hum CRC, BC






-2 I3C / DIM
Mod Hum BC, Cerv






-2 Thymoquinone
Early Hum BC, CRC






-2 Beta-carotene (food)
Hum Lung






-1 Vitamin K2 (MK-4/7)
Limited Hum Liv, PCa






-1 Boron
Obs PCa, Lung






0 Vitamin C (oral)
Strong Hum —






0 Genistein (soy)
Strong Hum BC, PCa






0 Selenium (diet)
Mixed Hum PCa






0 Capsaicin
Mixed Gastric






+2 Vitamin E (alpha only)
Strong RCT PCa






+2 Green tea extract (high-dose)
Case reports Liv






+4 Beta-carotene (supplement)
Strong RCT Lung (smokers)






+5 Alcohol (ethanol)
Strong Hum BC, Liv, Eso







Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use


Scientific Papers found: Click to Expand⟱
5416- ASA,    Cancer Incidence and Mortality With Aspirin in Older Adults
- Trial, Var, NA
Risk∅, OS∅,
5414- ASA,    Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Review, Var, NA
Risk↓, *toxicity↓, other↑, *COX1↓, TumCP↓, DNArepair↑, ChemoSen↑, other↓,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
5411- ASA,    Mechanistic Insights into a Classic Wonder Drug—Aspirin
- Review, Var, NA
*COX2↓, *COX1↓, *Inflam↓, *cardioP↑, Risk↓,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5409- ASA,    Role of aspirin in cancer prevention
- Review, Var, NA
Imm↑, *Inflam↓, *AntiAg↑, *GutMicro↑, eff↑, TumMeta↓, angioG↓, Risk↓, Risk↓,
5407- ASA,    Low-dose aspirin reduces the risk of colorectal cancer recurrence in patients with resected PI3K-altered localised disease, according to the ALASCCA trial.
- Trial, CRC, NA
Dose↝, Risk↓,
5405- ASA,    Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence
- Review, Var, NA
Risk↓, COX1↓, PGE2↓, Inflam↓, *AntiAg↓, PI3K↓, Akt↓, Risk↓,
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5399- ASA,    Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
- Trial, Nor, NA
Risk↝, Risk↑, Risk∅, Risk↑, other↝,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Akt↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 4,   other↑, 1,   other↝, 4,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,  

Migration ⓘ

KRAS↓, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   Imm↑, 1,   Inflam↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 3,   eff↑, 1,  

Clinical Biomarkers ⓘ

KRAS↓, 1,  

Functional Outcomes ⓘ

OS∅, 1,   Risk↓, 14,   Risk↑, 2,   Risk↝, 1,   Risk∅, 2,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Transcription & Epigenetics ⓘ

other↑, 1,  

Migration ⓘ

AntiAg↓, 1,   AntiAg↑, 3,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 4,   COX2↓, 2,   Inflam↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   Half-Life↓, 2,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   toxicity↓, 1,  
Total Targets: 12

Scientific Paper Hit Count for: Risk, Risk
12 Aspirin -acetylsalicylic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:1  Target#:785  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page